Lilly’s Antibody Clinical Trial in Nursing Homes Prevents COVID-19, Reduces Resident Risk Up to 80%

A Phase 3 clinical trial of an antibody drug that enrolled residents and staff at skilled nursing and assisted living facilities found that the treatment significantly reduced the risk of contracting symptomatic COVID-19. The antibody drug, bamlanivimab (LY-CoV555), was developed by pharmaceutical giant Eli Lilly and Company (NYSE: LLY) for clinical use with the Vancouver-based […]

How Lilly’s COVID-19 Nursing Home Trial Could Change the Future of Research in Long-Term Care

In normal times, setting up a clinical trial can take nine months or more, with the actual work going on for potentially years afterwards. But during COVID-19, researchers don’t have the benefit of time — especially when working to find therapeutic options for vulnerable seniors in nursing homes. *A phase-three clinical trial for a new […]